Autoantibodies Targeting GPCRs and RAS-related Molecules Associate with COVID-19 Severity

COVID-19 shares the feature of autoantibody production with systemic autoimmune diseases. In order to understand the role of these immune globulins in the pathogenesis of the disease, it is important to explore the autoantibody spectra. Here we show, by a cross-sectional study of 246 individuals, that autoantibodies targeting G protein-coupled receptors (GPCR) and RAS-related molecules associate with the clinical severity of COVID-19. Patients with moderate and severe disease are characterized by higher autoantibody levels than healthy controls and those with mild COVID-19 disease. Among the anti-GPCR autoantibodies, machine learning classification identifies the chemokine receptor CXCR3 and the RAS-related molecule AGTR1 as targets for antibodies with the strongest association to disease severity. Besides antibody levels, autoantibody network signatures are also changing in patients with intermediate or high disease severity. Although our current and previous studies identify anti-GPCR antibodies as natural components of human biology, their production is deregulated in COVID-19 and their level and pattern alterations might predict COVID-19 disease severity.

Citing Articles

NETosis: A key player in autoimmunity, COVID-19, and long COVID.

Monsalve D, Acosta-Ampudia Y, Acosta N, Celis-Andrade M, Sahin A, Yilmaz A J Transl Autoimmun. 2025; 10:100280.

PMID: 40071133 PMC: 11894324. DOI: 10.1016/j.jtauto.2025.100280.

Dysregulated autoantibodies targeting AGTR1 are associated with the accumulation of COVID-19 symptoms.

Fonseca D, Japel M, Gyamfi M, Filgueiras I, Baiochi G, Ostrinski Y NPJ Syst Biol Appl. 2025; 11(1):7.

PMID: 39805853 PMC: 11730328. DOI: 10.1038/s41540-025-00488-z.

Autoantibodies Targeting G-Protein-Coupled Receptors and RAS-Related Molecules in Post-Acute COVID Vaccination Syndrome: A Retrospective Case Series Study.

Mantovani M, Bellavite P, Fazio S, Di Fede G, Tomasi M, Belli D Biomedicines. 2025; 12(12.

PMID: 39767757 PMC: 11673082. DOI: 10.3390/biomedicines12122852.

Efficacy of repeated immunoadsorption in patients with post-COVID myalgic encephalomyelitis/chronic fatigue syndrome and elevated β2-adrenergic receptor autoantibodies: a prospective cohort study.

Stein E, Heindrich C, Wittke K, Kedor C, Rust R, Freitag H Lancet Reg Health Eur. 2025; 49:101161.

PMID: 39759581 PMC: 11699797. DOI: 10.1016/j.lanepe.2024.101161.

Brain-wide alterations revealed by spatial transcriptomics and proteomics in COVID-19 infection.

Zhang T, Li Y, Pan L, Sha J, Bailey M, Faure-Kumar E Nat Aging. 2024; 4(11):1598-1618.

PMID: 39543407 PMC: 11867587. DOI: 10.1038/s43587-024-00730-z.

References

Rahmati S, Abovsky M, Pastrello C, Kotlyar M, Lu R, Cumbaa C . pathDIP 4: an extended pathway annotations and enrichment analysis resource for human, model organisms and domesticated species. Nucleic Acids Res. 2019; 48(D1):D479-D488. PMC: 7145646. DOI: 10.1093/nar/gkz989. View

Halpert G, Shoenfeld Y . SARS-CoV-2, the autoimmune virus. Autoimmun Rev. 2020; 19(12):102695. PMC: 7598743. DOI: 10.1016/j.autrev.2020.102695. View

Ehrenfeld M, Tincani A, Andreoli L, Cattalini M, Greenbaum A, Kanduc D . Covid-19 and autoimmunity. Autoimmun Rev. 2020; 19(8):102597. PMC: 7289100. DOI: 10.1016/j.autrev.2020.102597. View

Rose L, Graham L, Koenecke A, Powell M, Xiong R, Shen Z . The Association Between Alpha-1 Adrenergic Receptor Antagonists and In-Hospital Mortality From COVID-19. Front Med (Lausanne). 2021; 8:637647. PMC: 8048524. DOI: 10.3389/fmed.2021.637647. View

Heyman S, Walther T, Abassi Z . Angiotensin-(1-7)-A Potential Remedy for AKI: Insights Derived from the COVID-19 Pandemic. J Clin Med. 2021; 10(6). PMC: 8001321. DOI: 10.3390/jcm10061200. View

Pombinho R, Pinheiro J, Resende M, Meireles D, Jalkanen S, Sousa S . Stabilin-1 plays a protective role against Listeria monocytogenes infection through the regulation of cytokine and chemokine production and immune cell recruitment. Virulence. 2021; 12(1):2088-2103. PMC: 8366540. DOI: 10.1080/21505594.2021.1958606. View

Konig M, Powell M, Staedtke V, Bai R, Thomas D, Fischer N . Preventing cytokine storm syndrome in COVID-19 using α-1 adrenergic receptor antagonists. J Clin Invest. 2020; 130(7):3345-3347. PMC: 7324164. DOI: 10.1172/JCI139642. View

Kanduc D, Shoenfeld Y . Molecular mimicry between SARS-CoV-2 spike glycoprotein and mammalian proteomes: implications for the vaccine. Immunol Res. 2020; 68(5):310-313. PMC: 7499017. DOI: 10.1007/s12026-020-09152-6. View

Chami B, Yeung A, Buckland M, Liu H, Fong G, Tao K . CXCR3 plays a critical role for host protection against Salmonellosis. Sci Rep. 2017; 7(1):10181. PMC: 5579293. DOI: 10.1038/s41598-017-09150-z. View

10.

Cabral-Marques O, Riemekasten G . Functional autoantibodies targeting G protein-coupled receptors in rheumatic diseases. Nat Rev Rheumatol. 2017; 13(11):648-656. DOI: 10.1038/nrrheum.2017.134. View

11.

Wang E, Mao T, Klein J, Dai Y, Huck J, Jaycox J . Diverse functional autoantibodies in patients with COVID-19. Nature. 2021; 595(7866):283-288. DOI: 10.1038/s41586-021-03631-y. View

12.

Regan D, Coy J, Chahal K, Chow L, Kurihara J, Guth A . The Angiotensin Receptor Blocker Losartan Suppresses Growth of Pulmonary Metastases via AT1R-Independent Inhibition of CCR2 Signaling and Monocyte Recruitment. J Immunol. 2019; 202(10):3087-3102. PMC: 6504574. DOI: 10.4049/jimmunol.1800619. View

13.

Cantuti-Castelvetri L, Ojha R, Pedro L, Djannatian M, Franz J, Kuivanen S . Neuropilin-1 facilitates SARS-CoV-2 cell entry and infectivity. Science. 2020; 370(6518):856-860. PMC: 7857391. DOI: 10.1126/science.abd2985. View

14.

Khamsi R . Rogue antibodies could be driving severe COVID-19. Nature. 2021; 590(7844):29-31. DOI: 10.1038/d41586-021-00149-1. View

15.

Vasanthakumar N . Beta-Adrenergic Blockers as a Potential Treatment for COVID-19 Patients. Bioessays. 2020; 42(11):e2000094. PMC: 7460992. DOI: 10.1002/bies.202000094. View

16.

Rothlin R, Duarte M, Pelorosso F, Nicolosi L, Salgado M, Vetulli H . Angiotensin Receptor Blockers for COVID-19: Pathophysiological and Pharmacological Considerations About Ongoing and Future Prospective Clinical Trials. Front Pharmacol. 2021; 12:603736. PMC: 8039444. DOI: 10.3389/fphar.2021.603736. View

17.

Qin S, Rottman J, Myers P, Kassam N, Weinblatt M, Loetscher M . The chemokine receptors CXCR3 and CCR5 mark subsets of T cells associated with certain inflammatory reactions. J Clin Invest. 1998; 101(4):746-54. PMC: 508621. DOI: 10.1172/JCI1422. View

18.

Cabral-Marques O, Marques A, Giil L, De Vito R, Rademacher J, Gunther J . GPCR-specific autoantibody signatures are associated with physiological and pathological immune homeostasis. Nat Commun. 2018; 9(1):5224. PMC: 6283882. DOI: 10.1038/s41467-018-07598-9. View

19.

Dotan A, Muller S, Kanduc D, David P, Halpert G, Shoenfeld Y . The SARS-CoV-2 as an instrumental trigger of autoimmunity. Autoimmun Rev. 2021; 20(4):102792. PMC: 7892316. DOI: 10.1016/j.autrev.2021.102792. View

20.

Lichtman A . Anti-body antibodies in COVID-19. Sci Immunol. 2021; 6(60). DOI: 10.1126/sciimmunol.abj7173. View